Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00110214 · ClinicalTrials.gov registry record · Phase 3

Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

A Phase 3 study of Recurrent Prostate Cancer and Stage IV Prostate Cancer, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 3
Development phase
1,050
Enrollment target
2
Study locations

NCT00110214 is a Phase 3 study of Recurrent Prostate Cancer and Stage IV Prostate Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 1,050 participants, above the 89-participant average among 21 other Recurrent Prostate Cancer trials with a reported enrollment target (1080% higher). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00110214, a Phase 3 study of Recurrent Prostate Cancer and Stage IV Prostate Cancer, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 3
Development phase
1,050 participants
Enrollment target
2
Study locations

Study Summary

This randomized phase III trial is studying docetaxel, prednisone, and bevacizumab to see how well they work compared to docetaxel and prednisone in treating patients with prostate cancer that did not respond to hormone therapy. Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. It is not yet known whether docetaxel, prednisone, and bevacizumab are more effective than docetaxel and prednisone in treating prostate cancer.

Conditions Studied

Recurrent Prostate Cancer Stage IV Prostate Cancer Adenocarcinoma of the Prostate Hormone-Resistant Prostate Cancer

Interventions

  • OTHER laboratory biomarker analysis
  • DRUG prednisone
  • OTHER placebo
  • DRUG docetaxel
  • BIOLOGICAL bevacizumab

Study Locations (2)

Connecticut

  • Yale University - New Haven

Illinois

  • Cancer and Leukemia Group B - Chicago

Trial Details

FieldValue
Enrollment Target 1,050 participants
Start Date 2005-04
Est. Completion 2011-08
Phase Phase 3

Sponsor

National Cancer Institute (NCI)

3,257 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00110214

The ClinicalTrials.gov registry entry for NCT00110214 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,050 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 89-participant average among 21 other Recurrent Prostate Cancer trials with a reported enrollment target (1080% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Recurrent Prostate Cancer appearing as the primary indexed condition, and to 5 interventions - of which laboratory biomarker analysis is the first listed.

NCT00110214 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Connecticut, Illinois.

Frequently Asked Questions

What is clinical trial NCT00110214 about?

NCT00110214 is a clinical study titled "Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy". This randomized phase III trial is studying docetaxel, prednisone, and bevacizumab to see how well they work compared to docetaxel and prednisone in treating patients with prostate cancer that did not respond to hormone therapy. Drugs used in chemotherapy, such as docetaxel and prednisone, work in d...

What is the current status of trial NCT00110214?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,050 participants. The study started on 2005-04. Estimated completion is 2011-08.

What conditions does trial NCT00110214 study?

This clinical trial studies the following conditions: Recurrent Prostate Cancer, Stage IV Prostate Cancer, Adenocarcinoma of the Prostate, Hormone-Resistant Prostate Cancer.

What interventions are being tested in trial NCT00110214?

The interventions under investigation include: laboratory biomarker analysis (OTHER), prednisone (DRUG), placebo (OTHER), docetaxel (DRUG), bevacizumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT00110214?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00110214 being conducted?

This trial has 2 study locations across Connecticut, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Recurrent Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Recurrent Prostate Cancer

All registered trials for this condition

Stage IV Prostate Cancer

All registered trials for this condition

Connecticut

All trials with a study site in Connecticut

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.